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Abstract
Modern humans, the longest-living terrestrial mammals, display short telomeres and
repressed telomerase activity in somatic tissues compared with most short-living small
mammals. The dual trait of short telomeres and repressed telomerase might render humans
relatively resistant to cancer compared with short-living small mammals. However, the
trade-off for cancer resistance is ostensibly increased age-related degenerative diseases,
principally in the form of atherosclerosis. In this communication, we discuss (a) the genetics
of human telomere length, a highly heritable complex trait that is influenced by genetic
ancestry, sex, and paternal age at conception, (b) how cancer might have played a role in
the evolution of telomere biology across mammals, (c) evidence that in modern humans
telomere length is a determinant (rather than only a biomarker) of cancer and atherosclero-
sis, and (d) the potential influence of relatively recent evolutionary forces in fashioning the
variation in telomere length across and within populations, and their likely lasting impact on
major diseases in humans. Finally, we propose venues for future research on human telo-
mere genetics in the context of its potential role in shaping the modern human lifespan.
Introduction
In mammals, telomeres consist of TTAGGG tandem repeats and their binding proteins, which
together cap and protect the ends of chromosomes [1]. Telomeres experience progressive
shortening with successive cell replications, ultimately reaching a critically short length, trig-
gering replicative senescence, which might be one of the mechanisms that drive aging of tissues
and organs in vivo [2,3]. A body of data exists on telomere length (TL) dynamics (TL and its
age-dependent attrition) and the association of TL with human diseases. These include a num-
ber of aging-related disorders that belong to the two disease categories that largely shape the
lifespan of humans in high- and middle-income countries: cancer and atherosclerotic cardio-
vascular disease (CVD). Still, a clear conceptual framework for the role of telomere biology in
the evolution of human health and disease is lacking. Moreover, earlier research promoted the
PLOSGenetics | DOI:10.1371/journal.pgen.1006144 July 7, 2016 1 / 10
a11111
OPEN ACCESS
Citation: Stone RC, Horvath K, Kark JD, Susser E,
Tishkoff SA, Aviv A (2016) Telomere Length and the
Cancer–Atherosclerosis Trade-Off. PLoS Genet 12
(7): e1006144. doi:10.1371/journal.pgen.1006144
Editor: Elizabeth M. C. Fisher, University College
London, UNITED KINGDOM
Published: July 7, 2016
Copyright: © 2016 Stone et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Funding: This research was supported by awards
from the National Institutes of Health to Dr. Ezra
Susser (R01HD071180), Dr. Sarah Tishkoff
(R01GM113657, R01DK104339), and Dr. Abraham
Aviv (R01HL116446, R01HD071180). The funders
had no role in the preparation of the article.
Competing Interests: The authors have declared
that no competing interests exist.
view that short TL, as expressed in leukocytes, is a non-causal biomarker of increased risk for
aging-related diseases. In contrast, more recent research based on the analysis of genetic deter-
minants of TL and on Mendelian randomization studies using single nucleotide polymor-
phisms (SNPs) as proxies for TL suggests that TL might play a causal role in a number of
cancers [4–6] and in atherosclerotic CVD [7].
General Characteristics of Telomere Length in Humans
Homo sapiens displays short TL compared with most other mammalian species [8] and
repressed activity in somatic tissues of telomerase [8–10], the reverse transcriptase that uses its
RNA template to add telomere repeats to the DNA termini [1]. During fetal development, a
similar TL is maintained across somatic cells [11,12], including cells in the hematopoietic sys-
tem [13]. That is, fetuses and newborns with short (or long) TL in one tissue display short (or
long) TL in other tissues. During postnatal growth and development, some tissues exhibit
more TL shortening than others; for example, there is more TL attrition in the highly prolifer-
ative hematopoietic system than in much less proliferative muscle tissue. However, the similar-
ity in TL across tissues that has been established by adulthood is largely maintained over the
remaining life course [14].
Knowledge of TL dynamics in humans is primarily based on research using leukocytes. Leu-
kocyte TL (LTL) is highly familial with about 65% heritability; the heritability of age-dependent
LTL attrition (in adults) is about 30% [15–18]. In addition, sex (females have longer LTL than
males [16,19,20]), ancestry (African Americans [21] and sub-Saharan Africans [22] have lon-
ger LTL than individuals of European ancestry), and father’s age at conception (offspring of
older fathers have longer LTL than those of younger fathers [23–26]) also influence LTL. Envi-
ronmental factors, including socioeconomic status [27], smoking [19,28], sedentary lifestyle
[29], energy intake [30], and perhaps mental stress [31,32] might be associated with a short
LTL, suggesting that these factors might influence or be influenced by LTL dynamics to some
extent.
On average, mean LTL at birth is 9.5 kb in Europeans with a wide range of variation across
newborns [11,33,34]. Although LTL undergoes progressive shortening with age, the LTL vari-
ance observed in newborns is largely maintained during the life course [11,14]. At the age of 20
years, mean LTL is about 7.8 kb. Thereafter, the average LTL attrition approximates 25 base
pairs per year [35]. Little is known about inter-individual variation in LTL attrition during
growth and development based on longitudinal study design. Longitudinal studies show that
LTL attrition during adulthood does vary across individuals within a given population, but for
the overwhelming majority of the population, the inter-individual variation in this attrition is
typically of a magnitude that is insufficient to produce a substantial change in an individual’s
LTL percentile ranking compared with peers [36]. Based on the findings in fetuses [12], new-
borns [11,13,33,34], and adults [14,36,37], and on modeling of LTL attrition during growth
[38], we infer that LTL at birth is a major determinant of LTL in adults, such that newborns
with short (or long) LTL are likely to have short (or long) LTL throughout their life course
[39,40].
The Genetics of Leukocyte Telomere Length
LTL is a complex genetic trait. A series of population-based genome-wide association studies
(GWAS) has identified genetic loci associated with LTL. To date, 11 LTL-associated loci have
been identified in cohorts of Europeans [7,41–44], and many more genetic loci associated with
LTL remain to be identified and characterized across populations. Some of the loci that have
already been found to be associated with LTL harbor genes that are engaged in telomere
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maintenance. These include genes encoding the two major subunits of telomerase, the telome-
rase reverse transcriptase (TERT) and its RNA component (TERC), two of the members of the
human CST (CTC1, STN1, and TEN1) complex, i.e., CTC1 and STN1 (OBFC1), telomerase
ribonucleoprotein nuclear assembly factor 1 (NAF1), and telomere length maintenance gene
regulator of telomere helicase 1 (RTEL1) [7,41,42,44]. The exact roles of several other LTL-
associated genes in TL regulation are poorly understood; these include zinc finger proteins
ZNF208 and ZNF676, neutrophil trafficking chemokine CXCR4, and DCAF4, which is involved
in the ultraviolet radiation-induced DNA damage response [7,42–44].
Major germ line mutations can cause critically short telomeres that might lead to bone mar-
row failure. For example, mutations in TERT and TERC as well as in telomere end-protective
shelterins (telomeric repeat binding factor 1 [TERF1] and TRF1-interacting nuclear factor 2
[TINF2]) lead to extremely short telomeres and the development of dyskeratosis congenita and
idiopathic pulmonary fibrosis, which typically present with aplastic anemia [45]. However,
these telomeropathies are uncommon and may not explain telomere-related diseases in the
general population.
Cancer as an Evolutionary Force Affecting Telomere Length
TL genetics should be considered in the context of evolutionary forces that have left their signa-
ture on the human genome. Inspection of the human genome reveals that of the approximately
22,000 currently annotated genes, 13,000 genes (about 60%) are linked to biological pathways
of “cancer” (as referenced in the Ingenuity Knowledge Base [www.ingenuity.com]). These
include genes engaged in growth, development, tissue regeneration, and tissue renewal, which
heighten cancer risk due to increased cell replication, and genes that suppress cancer, including
those that ultimately promote senescence and apoptosis [46]. Central among cancer-protective
pathways might be telomere-driven replicative senescence [47].
Stem cells are likely to undergo more replications in large, long-living mammals than in
small, short-lived ones; this is because more replications are necessary for developing and
maintaining a larger body size. More cell replication confers increased risk of cancer through
accumulating de novo somatic mutations, which happen during successive DNA replications.
This concept is supported by work showing that the risk of developing major human cancers is
related to the number of stem cell divisions occurring in the tissues from which the cancers
originated [48,49]. Yet, large, long-living mammals generally display no increase in cancer risk
compared to small, short-lived ones, a phenomenon known as Peto’s paradox [50], suggesting
that mechanisms have evolved to mitigate cancer risk in tandem with increasing body size and
longevity [51,52]. One such mechanism has been described in elephants. The elephant genome
contains many more copies of TP53, a potent DNA damage response and tumor suppressor
gene; p53-dependent apoptosis is thus triggered at a lower threshold of accumulating muta-
tions, conferring cellular resistance to oncogenic transformation [53].
Similarly, a telomere-linked mechanism has been proposed in mammals based upon obser-
vations that telomerase activity in somatic tissues tends to be inversely correlated with body
size [9,10] while TL is inversely related to lifespan [8]. Repressed telomerase and short telo-
meres would, therefore, limit replicative capacity in humans. In this way, short TL might curb
the accumulation of de novo mutations and reduce the probability of oncogenic transforma-
tion in large, long-living mammals.
Given the wide variation in TL across humans, might longer telomeres increase cancer risk?
While initial studies were inconsistent (perhaps partially due to flaws in study design and small
sample sizes [54]), more recent studies show that in individuals of European ancestry, long
telomeres, as expressed in LTL, are associated with increased risk for melanoma [4,55,56],
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adenocarcinoma of the lung [57–59], and cancers of the breast ([60], but see [61]), pancreas
[62], and prostate [63]. Moreover, Mendelian randomization studies using LTL-associated
SNPs support the inference that having a longer LTL has a causal relation to cancer risk [5,6].
Polygenetic Adaptation and Telomere Length
Complex traits that are influenced by multiple genetic loci may be targets of polygenic adapta-
tion [64,65], i.e., simultaneous shifts in frequencies of many alleles influencing a trait in
response to local adaptation during human evolutionary history. Collectively, however, these
alleles might ultimately explain a large proportion of the wide variation in LTL across humans.
An illustration of this concept comes from findings that individuals of European ancestry dis-
play shorter LTL than sub-Saharan Africans and African Americans, and that loci associated
with LTL show evidence of polygenic adaptation in Europeans compared to Africans [22].
Dark skin renders protection to Africans from the DNA-damaging effect of ultraviolet radi-
ation (UVR); such damage is a major risk factor for melanoma [66]. The northbound migra-
tion out of Africa approximately 20–40 thousand years ago was ostensibly associated with skin
depigmentation and thus increased sensitivity to UVR, which might have augmented the risk
of melanoma. The idea that melanoma acted as an evolutionary selective force in ancestral
humans has been challenged based on the assumption that the life span of ancestral humans
was relatively short, and melanoma principally strikes individuals during the post-reproductive
years [67]. However, this view does not consider that once surviving childhood, ancestral
humans lived much longer than originally thought, and considerable evidence indicates that
melanoma afflicts adults throughout the life course, including young adulthood [68]. One
mechanism whereby individuals with light skin might have attenuated the risk of melanoma is
by shortening their telomeres through polygenic adaptation, thereby explaining in part the
shorter LTL in individuals of European ancestry than in sub-Saharan Africans [22]. Simply
put, Europeans would have been even more susceptible to melanoma without polygenetic
adaptation-mediated TL shortening.
The Cancer–Atherosclerosis Trade-Off
The cancer protection conferred by short telomeres could come with an evolutionary trade-off
[69], namely, diminished proliferative activity of stem cells and consequently less regenerative
capacity. This would manifest in age-dependent degenerative diseases. Some of the leading
degenerative diseases in humans are related to atherosclerosis, and atherosclerosis is associated
with short LTL [40,70,71]. As cancer and atherosclerosis strongly impact longevity, the diamet-
rically opposing roles of TL in these two disorders might be relevant to understanding the life-
span of contemporary humans and future trajectories in life expectancy. Notably, in
evolutionary terms, this would probably have become more relevant when agrarian societies
emerged over the past ten thousand years or so and lifespans increased considerably. In fact,
evidence of atherosclerosis has been detected in ancient human Egyptian mummies [72].
Recent studies have used LTL GWAS findings to generate “genetic risk scores” for cancers
and for atherosclerosis insofar as it is expressed in coronary heart disease. These studies have
shown that the same cluster of LTL-associated alleles (OBFC1, ZNF208, TERC, TERT, RTEL1,
ACTP2, and NAF1) is a risk indicator for melanoma [4], lung cancer [57], and coronary heart
disease [7], such that when the joint effect of the alleles results in a comparatively long LTL, the
risk for melanoma and lung cancer is increased, whereas the risk for coronary heart disease is
diminished. The opposite holds when the joint effect of the alleles results in a comparatively
short LTL, which engenders a higher risk for coronary heart disease and a lower risk for cancer
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(Fig 1). This cancer–atherosclerosis trade-off might principally apply to contemporary humans
because they live so long, but not to ancestral humans.
Ancestry, Telomere Length, and the Cancer–Atherosclerosis
Trade-Off
In light of the longer LTL in African Americans than in individuals of European ancestry, it is
of interest to compare the incidence of major cancers and atherosclerosis in the two ethnicities.
The incidence of cancers of the lung (after adjustment for smoking), pancreas, and prostate is
higher in African Americans than in individuals of European ancestry [73–75]. The incidence
of triple-negative breast cancer is also higher in African American women, and its onset is at a
younger age than in women of European ancestry [76]. In contrast, in spite of increased risk
factors for atherosclerosis due to higher rates of type 2 diabetes, hypertension, left ventricular
hypertrophy, and low socioeconomic status, African Americans display a lower incidence of
atherosclerosis, as expressed in coronary artery calcification and coronary artery disease
[77,78].
Conclusions and Suggestions for Future Research
Converging lines of evidence point to a causal role of TL in the cancer–atherosclerosis trade-off
across humans. This trade-off has been principally established through the force of evolution.
In contrast to cancer, which is associated with over ten thousand genes, only several hundred
genes in the human genome have been shown to relate to atherosclerosis. Yet, atherosclerosis is
a major determinant in the longevity of humans because of their relatively long lifespan, espe-
cially in high- and middle-income societies.
We note, however, the paucity of comparative LTL data by ethnicity and that LTL GWAS
have been almost exclusively performed on individuals of European ancestry. Moreover, the
role of TL in the cancer–atherosclerosis trade-off has been shown thus far based on a few types
of cancers and an aggregate of less than a dozen SNPs. There are likely numerous other SNPs
Fig 1. Telomere length (TL) and the cancer–atherosclerosis trade-off at the genomic level. Alleles that are jointly associated with relatively short TL
diminish the risk for major cancers and increase the risk for atherosclerosis, while alleles (of the same SNPs) that are jointly associated with relatively long
TL increase the risk for major cancers and diminish the risk for atherosclerosis.
doi:10.1371/journal.pgen.1006144.g001
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throughout the genome that are associated with TL, and distinctive TL-mediated evolutionary
trade-offs have probably emerged within different global populations and at different periods
to accommodate their unique environmental settings. Therefore, large-scale measurements of
LTL and genome-wide genotyping (sequencing) of different ethnic groups residing in diverse
geographical regions across the globe will be essential to decipher the evolutionary signature in
human telomere biology and to gain further insight into the role of telomeres in human
diseases.
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